HealthEquity (HQY) Reports Q1 Earnings: What Key Metrics Have to Say

HealthEquity (HQY) reported Q1 revenue of $330.84 million, a 15% year-over-year increase, and EPS of $0.97, up from $0.80 in the prior year, both exceeding consensus estimates. Key metrics were mixed, with CDB accounts and total accounts surpassing analyst estimates, while total HSA assets, HSA investments, and HSA cash fell short; custodial and interchange revenues saw significant year-over-year growth of 28.6% and 14.4%, respectively. HealthEquity shares have outperformed the S&P 500 over the past month, and the stock holds a Zacks Rank #2 (Buy).

Analysis

HealthEquity (HQY) reported a strong first quarter for April 2025, with revenue of $330.84 million, marking a 15% year-over-year increase, and an EPS of $0.97, up from $0.80 in the corresponding period last year. Both top and bottom-line figures surpassed analyst expectations, with revenue exceeding the Zacks Consensus Estimate by 3.03% and EPS delivering a significant surprise of +19.75% against an estimate of $0.81. Despite these robust headline results, an examination of key operational metrics reveals a mixed performance. While CDBs Accounts (7.17 million vs. 6.86 million estimated) and Total Accounts (17.06 million vs. 16.92 million estimated) modestly beat analyst forecasts, core HSA-related figures such as Total HSA Assets ($31.27 billion vs. $32.13 billion estimate), Total HSA investments ($14.21 billion vs. $14.46 billion estimate), Total HSA cash ($17.07 billion vs. $17.67 billion estimate), and HSAs Accounts (9.89 million vs. 10.05 million estimate) all fell short of projections. Revenue segmentation showed particular strength in Custodial revenue, which climbed 28.6% year-over-year to $156.46 million, and Interchange revenue, up 14.4% to $54.61 million, both exceeding estimates. Service revenue grew 1.3% to $119.78 million, also slightly beating expectations. Reflecting this performance and positive sentiment, HealthEquity's shares have appreciated +12.5% over the past month, significantly outperforming the Zacks S&P 500 composite's +4.6% gain, and the stock currently holds a Zacks Rank #2 (Buy).

Key Decisions for Investors

• Investors should recognize the strong headline earnings and revenue beat, coupled with recent share price outperformance and a Zacks #2 (Buy) rank, as supportive of a continued positive near-term trajectory for HealthEquity.
• It is crucial to monitor key Health Savings Account (HSA) metrics, particularly total assets, investments, cash, and account numbers, as these underperformed analyst expectations despite overall account growth, potentially indicating areas for closer scrutiny in future quarters.
• The substantial year-over-year growth in Custodial revenue (+28.6%) and Interchange revenue (+14.4%), both of which also beat estimates, are significant positive contributors to profitability and should be watched for sustained momentum.